Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 1121 results for criteria

  1. Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (TA883)

    Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.

  2. Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.

  3. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]

    Topic prioritisation

  4. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

  5. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]

    Topic prioritisation

  6. Riluzole oral film for treating amyotrophic lateral sclerosis [TSID11779]

    Topic prioritisation

  7. Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]

    Topic prioritisation

  8. IgPro20 for treating dermatomyositis [TSID12014]

    Topic prioritisation

  9. Rezafungin for untreated invasive candidiasis [TSID10768]

    Topic prioritisation

  10. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

    This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).

  11. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

  12. Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TSID10755]

    Topic prioritisation

  13. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.